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ABSTRACT		
Objectives:	Since	the	early	1990’s	the	low	long-term	survival	rates	following	pancreatic	surgery	 for	 pancreatic	 ductal	 adenocarcinoma	 (PDAC)	 challenged	 to	 improve	 the	treatment.	In	this	series	we	aim	to	show	improved	survival	from	PDAC	during	the	era	of	centralized	pancreatic	surgery.	
Methods:	 All	 pancreatic	 resections	 operated	 at	 Helsinki	 University	 Hospital	 and	 the	survival	of	PDAC	patients	during	2000-13	were	analysed.	Post-operative	complications	such	 as	 fistulas,	 reoperations	 and	mortality	 rates	were	 recorded.	 Patient	 and	 tumour	characteristics	were	compared	with	survival	data.		
Results:	 Of	 the	 853	 patients	 undergoing	 pancreatic	 surgery,	 there	 were	 581	 (68%)	pancreaticoduodenectomies,	 195	 (21%)	 distal	 resections,	 28	 (3%)	 total	pancreatectomies,	 and	 49	 (6%)	 other	 procedures.	 Mortality	 after	pancreaticoduodenectomy	was	2.1%.	Clinically	 relevant	B/C	 fistula	 rate	was	7%	after	pancreaticoduodenectomy	and	13%	after	distal	 resection.	 	Re-operation	 rate	was	5%.	The	5-	and	10-year	survival	rates	for	PDAC	were	22	%	and	14	%;	for	T1-2,	N0	and	R0	tumours,	the	corresponding	survival	rates	were	49%	and	31%.	CA19-9	>	75	kU/l,	CEA	>	5	µg/l,	N1,	LNR	>20%,	R1	and	lack	of	adjuvant	therapy	were	independent	risk	factors	for	decreased	survival.		
Conclusion:	After	centralization	of	pancreatic	surgery	in	Southern	Finland,	we	have	managed	to	enable	PDAC	patients	survive	markedly	longer	than	in	the	early	1990’s.	Based	on	a	1.7-million	population	in	our	clinic,	mortality	rates	are	equal	to	those	of	other	high-volume	centres	and	long-term	survival	rates	for	PDAC	have	now	risen	to	one	of	the	highest	reported.
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INTRODUCTION	
Pancreatic surgery has a high morbidity rate, and even very high-volume hospitals report high 
postoperative mortality. In hospital, 30-day or 60-day mortality in high volume centres for 
pancreatic-head resections varies between 0.9 and 8.1% (1-5). In a very high-volume centre 
in Heidelberg, Germany, with a case load more than 2000 pancreaticoduodenectomies, the 
in-hospital mortality rate was 3.9% (5). Overall morbidity after pancreaticoduodenectomy is 
even 59% and 27% of them being serious adverse events (6, 7). Post-operative pancreatic 
fistula is one of the most serious complications and may lead to death.  
 
Overall long-term survival (> 5 years) of pancreatic ductal adenocarcinoma (PDAC), varies 
from 0 to 18 % (4, 8-10). In debate of the accuracy of histological diagnosis of PDAC one 
suggestion is that diagnosis of all long-time survivors needs re-evaluation by experienced 
pancreatic pathologists (8).   
 
Only a few reports from high-volume centres have indicated longer survival for a certain very 
small proportion of PDAC patients (2, 4, 9). These cases contribute 5-6% of all patients 
operated on for PDAC (2, 4). 
 
Former high postoperative mortality and complication rates and very low long-term survival 
rates for PDAC after pancreatic surgery have led to demand for improved treatment for this 
devastating disease. Internationally, centres for pancreatic surgery have been established 
with a multidisciplinary treatment. By this approach diagnostic accuracy of PDAC, 
postoperative mortality, and long-term survival for PDAC patients could be improved 
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remarkably (11-14). In southern Finland all pancreatic resections were centralized to Helsinki 
University Hospital, having 1.7 million population basis from the year 2000. 
Aim	
The aim of this study was to evaluate the outcome of patients undergoing pancreatic surgery 
in general as well as the possible survival benefits of PDAC patients in our hospital during 
centralization.  
 
PATIENTS	AND	METHODS	
From Helsinki University Hospital database we identified all patients undergoing pancreatic 
surgery other than necrosectomy between January 2000 and September 2013. Survival data 
came from patient records and from Finnish population registry on September 2014. Cause 
of death (COD) from pancreatic cancer or unrelated cause were analyzed. Information on age, 
gender, American Society of Anesthesiologists Physical Status Classification (ASA), tumour 
histology, grade, Union for International Cancer Control (UICC) TNM-stage, lymph-node 
status, margin-resection status (R, considered R0 when the clear resection margin is > 1 mm), 
type of resection, complications, adjuvant therapy, and tumour-marker levels came from 
patient records. Postoperative pancreatic fistula rates were analysed according to the 
international study group of post-operative pancreatic fistula (ISGPF) criteria (15).   
Our pancreaticoduodenectomy operation technique was developed during the 1990’s to 
become a standardised procedure by the year 2000. In malignant disease, operations started 
with laparoscopy to exclude peritoneal metastases. When none were detected, a transverse 
laparotomy followed. Pancreatic resection was according to the non-touch en-block principal 
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including distal gastrectomy. Resection included right-sided omentectomy, excision of the 
right cranial peritoneal leaf of the transverse colon exposing the caval vein and renal veins. 
Excision of the lymph nodes of the hepaticoduodenal ligament, around the right side of the 
caeliac axis, and excision of the aorto-caval notch caudally to the inferior arterial mesenterial 
axis, as well as along the anterior and right lateral side around the origin of the superior 
mesenteric artery were performed. If the tumour infiltrated the superior mesenteric or portal 
vein a resection was performed. Pancreatico-jejunal anastomosis was routinely performed 
end-to-side with a double-layer duct-to-mucosa suture line. All the patients were referred to 
adjuvant therapy. Neo-adjuvant therapy was administered when the tumour was 
radiologically borderline resectable (16). 
All histological specimens were re-evaluated and the diagnosis for PDAC was made by two 
experienced pancreatic pathologists. All slides from 2000-2006 were re-evaluated by both our 
local pancreatic pathologist (S.N.) and a German pancreatic pathologist (J.L.). Centralisation 
of surgery in time led to centralization of pathology, as well, and specimens from 2007 and 
later were re-evaluated locally (S.N.). Pancreatic malignancies other than PDAC were 
excluded from survival analysis. 
 
This study complies with the declaration of Helsinki and was approved by the Surgical Ethics 
Committee of Helsinki University Hospital, and the National Supervisory Authority of Welfare 
and Health. 
Statistics	
Life tables were calculated according to the Kaplan-Meier survival analysis, and the log rank 
test served for comparisons. Pancreatic cancer-specific overall survival was calculated from 
 6 
date of operation to death. Cox proportional hazards regression served for multivariate 
analysis. The Cox model assumption of constant hazard ratios over time was tested by 
including the time dependent covariate separately for each testable variable, when the 
assumption was valid. Variables included in the analyses were T-classification, N-
classification, disease-free margin R0, lymph-node ratio below 20%, adjuvant treatment, 
grade, and perivascular invasion, CA19-9 < 75 kU/l, CEA < 5.0 µg/l. Backward conditional 
stepping removed insignificant variables at p<0.1. Results are age- and sex-adjusted. All 
statistical analyses were performed with SPSS (v21, IBM, New York). Statistical significance 
was p < 0.05. 
 
RESULTS	
From January 2000 to September 2013, 853 patients underwent pancreatic surgery, (Table 
1). Of the 853, 581 (68%) patients underwent pancreaticoduodenectomy, 195 (21%) distal 
pancreatic resection, 28 (3%) total pancreatectomy and 49 (6%) other pancreatic procedures 
such as middle pancreatic resection, enucleation, or uncinate resection.  
 
Post-operative	outcome	
Out of 853, 13 (1.5%) patients died post-operatively. The in-hospital mortality after 
pancreaticoduodenectomy was 2.1 % (Table 2.) Clinically relevant grade B or C fistulas 
occurred in 7 % after pancreaticoduodenectomy and in 13 % after distal resection (Table 2). 
There were 44 (5%) patients who were re-operated.  
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Histological diagnosis was PDAC for 309 patients. After excluding those cases with a diagnosis 
not congruent, 306 patients remained for final analysis (Table 3). Of the PDAC patients, 52 
(17%) received neoadjuvant therapy, consisting of either gemcitabine, gemcitabine combined 
with cisplatin, oxaliplatin, or radiation therapy. There were 151 (53%, information was 
available on 285 patients) patients who received adjuvant therapy, mainly gemcitabine or its 
combination with cisplatin, kabesitabine, or radiation therapy. There were 23 (8%) patients 
who turned out to have metastasis at imaging after surgery before they had received adjuvant 
therapy (occult metastasis during surgery), and these patients received palliative therapy. 
 
Long-term	outcome 
The overall one-, three-, five- and ten-year survival rates for the 306 patients radically 
operated for PDAC were 74%, 36%, 22% and 14% (Table 4). In univariate analysis longer 
survival was significantly associated with CA19-9 < 75 kU/l (p=0.001), CEA < 5.0 µg/l (p=0.001), 
smaller tumor (T1-2) (p<0.001), lack of the lymph node metastasis (p=0.001) or LNR < 20% 
(p=0.001), higher histological differentiation grade (p=0.004), lack of perivascular invasion 
(p=0.001), and adjuvant therapy (p=0.016)  (Table 5, Fig 1.). Lack of perineural invasion was 
associated with a tendency for better survival (p=0.055) (Table 5). Neither age, gender, ASA 
class, nor neoadjuvant therapy was significantly associated with survival.  
 
When the R0N0 and tumour stage T1-2 patients (n=49, 16%) were analysed separately, their 
survival rates for five and ten years were 49% and 31% (median survival 46 vs. 23 months, 
p<0.001) (Table 3). More than half of the N1 patients (111, 57 %) received adjuvant therapy 
and benefitted significantly from it (median survival 25 vs. 13 months, p=0.021). 
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In multivariate analysis, patients who received post-operative adjuvant treatment had a 
significantly decreased hazard ratio, while patients with N1 status or patients with R1 had 
significantly poorer, increased hazard ratios than did patients with N0-status, radical 
operation (R0), and who had received no adjuvant treatment. Patients with CA19-9 > 75 
kU/l, CEA > 5.0 µg/l, LNR > 20 % also had significantly increased hazard ratios (Table 6).  
Multivariate analyses were adjusted for age and sex.  
DISCUSSION	
Since the beginning of the year 2000 the population basis of our hospital has increased to 1.7 
million. Larger hospital volume and improved surgical treatment may explain our very low 
post-operative in-hospital mortality rate nowadays of 2.1% after pancreaticoduodenectomy, 
which is at the same level as reported from very-high-volume international pancreatic 
centres. For example, Johns Hopkins Hospital in the U.S.A. has reported 1-2% postoperative 
mortality rates among almost 1500 pancreaticoduodenectomies, and Heidelberg in Germany, 
an in-hospital mortality of 3.9% after more than 2000 pancreatic resections (2, 5). In one 
Japanese pancreatic surgery database with 8575 pancreaticoduodenectomies the in-hospital 
mortality was 2.8% (17).   
 
In our hospital a clinically relevant ISGPF grade B or C fistula occurred in 7% of the patients 
who had undergone pancreaticoduodenectomy. Johns Hopkins Hospital reported a 5% fistula 
rate after pancreaticoduodenectomy (2). The variation has been high (5-16%) in different 
centres (5, 17). After distal resections fistula rates vary even more (0-40%) (5, 18). In our 
hospital the grade B or C fistula rate after distal resection was 13%. Several attempts have 
been made to reduce the number of fistulas by different surgical techniques and with 
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somatostatine analogues. A Cochrane analysis recommended octreotide for high-risk patients 
only (19). Prophylactic pasireotide has decreased the number of clinically significant fistulas 
to half in a recent randomized single centre study (20). Pasireotide has been in prophylactic 
use in our centre since that publication, but after the current study period. 
 
In our series, the overall 5-year survival of PDAC was 22% and in a subgroup of patients with 
T1-2, N0, and R0 tumours (49 patients, 16% of all) the 5-year survival was a very high 49% and 
even the 10-year survival 31%. In 2006, at Johns Hopkins Hospital, the overall 5-year survival 
for pancreatic head cancer was 18%. When the tumour was < 3 cm, and well or moderately 
differentiated, radically operated (R0), and lymph nodes were free of cancer, 5-year survival 
improved to 43% (2). Patients with these features numbered 56 (4.8%) of 1175 
pancreaticoduodenectomies for pancreatic head cancer (2). In Heidelberg, the survival, 
among 1071, of almost similar group of 62 patients (5.8%) (tumour grading Tis-T2), the 5-year 
survival was 54% (4). In our series, Tis was considered high-grade dysplasia, and these patients 
were not included in PDAC survival analysis. One explanation for our notably good survival 
results may be that an increasing number of patients are operated on an earlier stage of the 
disease. In our series, tumour stage was T1-2 in 96 (32%) of the patients or the lymph nodes 
were free of metastasis in 105 (35 %) patients compared to other centres with a 76-78 % N1 
prevalence (2, 4). Several other favourable tumour characteristics such as CA19-9 < 75 kU/l, 
CEA < 5.0 µg/l, higher cancer-differentiation grade, and lack of perivascular invasion favoured 
longer survival in both univariate and multivariate analysis, as could be expected. Our results 
stress the need for earlier diagnosis of PDAC.  
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The role of extended lymphadenectomy has been under debate. In gastric cancer, the 
increased survival after D2 lymph node dissection encouraged us to change the surgical 
technique towards the same principle also in PDAC (21, 22). In some studies extended 
lymhadenectomy has led to an increased number of R0 resections associated with better 
survival. Whether extended lymphadenectomy improves overall survival remains beyond the 
scope of our study. Thus far, five prospective randomized studies show no survival benefit 
after extended lymphadenectomy. Conversely, one meta-analysis showed a decrease in two- 
and three-year survival after extended lymphadenectomy (4, 23-28). 
 
Covering the years 1990-96 a former Finnish study showed that only one patient with PDAC 
survived clearly longer than five years in Finland (8). There was a high number of misdiagnosis 
among the long-term survivors that were falsely listed in the tumour registry. Our current 
data are the results of the era of centralisation of pancreatic surgery. Also pathology has been 
centralized and with the increase of cases an increase of experience in that field was gained. 
In high-volume centres high diagnostic experience is achieved and therefore limited outside 
reference evaluation is needed. This was confirmed by two independent pathologists 
confirming the diagnosis of PDAC between 2000-2006 (S.N. and J.L.). In addition the 
classification of pancreatic tumours (WHO) has been unified and is in general use also due to 
the increasing amount of pancreatic resection specimen. 
 
In the Carpelan-Holmström’s study (2005) no patients (data from 1990-96) received 
oncological adjuvant treatment, although now it has become routine after pancreatic cancer 
surgery (8). In the 21th century, prospective randomized ESPAC 1-3 and CONCO-001 trials 
have shown that patients receiving adjuvant chemotherapy survive significantly longer (29, 
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30). Our retrospective series showed a similar result in favour of adjuvant therapy. 
Neoadjuvant therapy has in some series improved surgical results, raising the number of R0 
resections. Further randomized controlled studies are necessary (31, 32).  
CONCLUSIONS	
Pancreatic surgery is safe in high-volume centres. Our centre’s low hospital mortality for 
pancreaticoduodenectomy (2.1%) is similar to that reported from other high volume centres. 
Our long-term survival for PDAC is now one of the highest reported. Early detection and 
multidisciplinary treatment of PDAC is essential for better survival. During the era of 
centralisation of pancreatic (cancer) surgery more patients have lived markedly longer than 
did those operated on in the early 1990’s. 
 ACKNOWLEDGEMENTS	Mary	 and	 Georg	 C.	 Ehrnrooth	 foundation,	 Sigrid	 Juselius	 Foundation	 and	 Helsinki	University	Hospital	Research	Funds	are	acknowledged	for	supporting	the	study.	None	of	the	 foundations	 have	 been	 involved	 in	 the	 study	 design.	 Authors	 have	 no	 conflicts	 of	interest	to	disclose.		
 	 	
 12 
FIGURE	LEGEND 
 
Fig. 1. The association of A. preoperative CA19-9 < 75 kU/l (p=0.001), B. preoperative CEA < 
5.0 µg/l (p=0.001), C. tumor stage T1-2 (p<0.001), D. N-stage (p<0.001), E. LNR < 20 % 
(p<0.001), F. the disease free margins (R0) (p<0.001), G. the lymph node status and resection 
margin (p<0.001), H. small tumor stage (T1-2), no lymph node metastasis (N0) and clear 
resection margins (R0) (p<0.001), I. the histological differentiation grade (p=0.004), J. 
perivascular invasion (p=0.001) and K. adjuvant therapy compared to observation alone 
(p=0.016) on survival after the pancreatic resection in PDAC patients. 
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Fig. 1. The association of A. preoperative CA19-9 < 75 kU/l (p=0.001), B. preoperative CEA < 5.0 µg/l 
(p=0.001), C. tumor stage T1-2 (p<0.001), D. N-stage (p<0.001), E. LNR < 20 % (p<0.001), F. the disease 
free margins (R0) (p<0.001), G. the lymph node status and resection margin (p<0.001), H. small tumor 
stage (T1-2), no lymph node metastasis (N0) and clear resection margins (R0) (p<0.001), I. the 
histological differentiation grade (p=0.004), J. perivascular invasion (p=0.001) and K. adjuvant therapy 
compared to observation alone (p=0.016) on survival after the pancreatic resection in PDAC patients. 
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